ͼƬ dz̸ҩÎï´«ÊäϵͳÑо¿µÄ¼¸¸öÈȵã_ÁúÊ¢¹ú¼ÊappÏÂÔØ_±¸ÓÃÍøÕ¾ÓÎÏ·~

ÁúÊ¢¹ú¼ÊappÏÂÔØ_±¸ÓÃÍøÕ¾ÓÎÏ·~

µ±Ç°Î»ÖãºÖ÷Ò³ > ±ÏÒµÂÛÎÄ > ҽҩѧ > ҩѧ > >

dz̸ҩÎï´«ÊäϵͳÑо¿µÄ¼¸¸öÈȵã

À´Ô´::δ֪ | ×÷Õß:ÁúÊ¢¹ú¼ÊappÏÂÔØ_±¸ÓÃÍøÕ¾ÓÎÏ·~ | ±¾ÎÄÒÑÓ°Ïì ÈË

Õª¡¡Òª¡¡Í¨¹ý²éÔĽüÄê¹úÍâÎÄÏ×£¬Öصã½éÉÜÁËÒ©Îï´«Êäϵͳ½ÏеĽøÕ¹£¬ÓÐÂö³åʽ¸øҩϵͳ£¬½á³¦¶¨Î»¸øҩϵͳ¼°ÊÜÌåÐÍÓëÃâÒßÐÍ°ÐÏòÖƼÁµÈÄÚÈÝ¡£

¡¡¡¡¹Ø¼ü´Ê£ºÒ©Îï´«Êäϵͳ¡¡Âö³åʽ¸øҩϵͳ¡¡½á³¦¶¨Î»¸øҩϵͳ¡¡ÊÜÌåÐÍÓëÃâÒßÐÍ°ÐÏòÖƼÁ

¡¡¡¡Ò©Îï´«Êäϵͳ(Drug Delivery Systems,DDS)ϵָÈËÃÇÔÚ·ÀÖμ²²¡µÄ¹ý³ÌÖÐËù²ÉÓõĸ÷ÖÖÖÎÁÆÒ©ÎïµÄ²»Í¬¸øÒ©ÐÎʽ£¬ÔÚ60Äê´úÒÔÇ°µÄÒ©¼ÁѧÖгÆΪ¼ÁÐÍ¡£Èç×¢Éä¼Á¡¢Æ¬¼Á¡¢½ºÄÒ¼Á¡¢ÌùƬ¡¢ÆøÎí¼ÁµÈ¡£Ëæ×Å¿ÆѧµÄ½ø²½£¬¼ÁÐ͵ķ¢Õ¹ÒÑÔ¶Ô¶³¬Ô½ÆäÔ­ÓеÄÄÚº­£¬ÐèÒªÓÃÒ©Îï´«Êäϵͳ»ò¸øÒ©Æ÷(Device)ÕâÀàÊõÓï¼ÓÒÔ±íÊö£¬¼´Ô­ÓÉÒ©ÎïÓ븨ÁÏÖƳɵĸ÷ÖÖ¼ÁÐÍÒÑÂú×ã²»ÁËÁÙ´²ÖÎÁƵÄÐèÒª£¬ÓеĽ«Ò©ÎïÖƳÉÊäעϵͳ¹©Óã¬ÓеÄÔò²ÉÓÃîѺϽðÖƳɸøÒ©Æ÷Ö²ÈëÌåÄÚÓ¦Óã¬Ê¹ÁÙ´²ÓÃÒ©¸üÀíÏ뻯¡£Îª¿Ë·þÆÕͨÖƼÁµÄÓÐЧѪŨά³Öʱ¼ä¶ÌµÄȱÏÝ£¬³öÏÖÁ˳¤Ð§×¢Éä¼Á£¬¿Ú·þ³¤Ð§¸øҩϵͳ»ò»º/¿ØÊÍÖƼÁ¡¢¾­Æ¤¸øҩϵͳµÈһϵÁÐеÄÖƼÁ¡£ÓÉÓÚ»º/¿ØÊÍÖƼÁµÄÌص㣬ËüµÄÊг¡Ç°¾°¿´ºÃ¡£»ºÊÍÖƼÁͨ³£ÊÇÖ¸¿Ú·þ¸øÒ©ºóÄÜÔÚ»úÌåÄÚ»ºÂýÊÍ·ÅÒ©Îʹ´ïÓÐЧѪŨ£¬²¢ÄÜά³ÖÏ൱³¤Ê±¼äµÄÖƼÁ¡£¿ØÊÍÖƼÁϵָÊÍÒ©ËٶȽöÊܸøҩϵͳ±¾ÉíµÄ¿ØÖÆ£¬¶ø²»ÊÜÍâ½çÌõ¼þ£¬ÈçpH¡¢Ã¸¡¢Àë×Ó¡¢Î¸³¦È䶯µÈÒòËصÄÓ°Ïì£Û1£Ý£¬ÊÇ°´Éè¼ÆºÃµÄ³ÌÐò¿ØÖÆÊÍÒ©µÄÖƼÁ£¬ÈçÁ㼶ÊÍÒ©µÄÉø͸±Ã£¬Âö³åÊÍÒ©µÄ΢Í裬½á³¦¶¨Î»ÊÍÒ©µÄƬ¼Á»ò½ºÄÒÒÔ¼°×Ô¶¯µ÷½ÚÊÍÒ©µÄÒȵºËظøÒ©Æ÷µÈµÈ¡£ÒàÓÐЩÎÄÏ׶ԻºÊÍ¡¢¿ØÊÍÖƼÁ²»¼ÓÑϸñÇø·Ö£¬Í³³ÆΪ»º/¿ØÊÍÖƼÁ¡£

¡¡¡¡¹úÍâÏÖÓйæ¸ñ²»Í¬µÄ»º/¿ØÊÍÖƼÁÉÌÆ·´ïÊý°ÙÖÖÒÔÉÏ£¬Æä¼ÁÐÍÒàÓÐƬ¼Á¡¢½ºÄÒ¡¢Ë¨¼Á¡¢Éø͸±Ã¡¢Í¸Æ¤ÌùƬ¡¢Ò©Ìõ¡¢Ö²Èë¼Á¡¢Õ³Ä¤Õ³¸½¼Á¼°×¢Éä¼ÁµÈ¶àÖÖÐÎʽ£¬ÆäÖÐÒÔ¿Ú·þ»º/¿ØÊÍÖƼÁ·¢Õ¹×î¿ì¡£»ºÊÍ΢Í轺ÄÒ¼ÁÓ뻺ÊÍƬÏà±È£¬¾ßÓа²È«ÏµÊý¸ßµÄÌص㣬һ¸ö½ºÄÒÊÇÓÉÉÏ°ÙÁ£»ºÊÍ΢Íè×é³É£¬ÈôÓиö±ðСÍè½øÈë賦µÀºó·¢ÉúѸËÙ±À½âÊÍÒ©µÄÏÖÏó£¬ÆäÓ°ÏìÊÇ΢СµÄ£¬¶ø»ºÊÍƬÈôÓбÀÊÍÏÖÏó£¬ÒòÆäµ¥´Î¼ÁÁ¿±ÈÆÕͨÖƼÁ´ó£¬Æäºó¹ûÊDz»ÑÔ¶øÓ÷µÄÁË£»¶øÇÒ»ºÊÍ΢Í轺ÄÒ²»Ò׶Ôθ¿ÕËÙÂÊÂýµÄ»¼Õß·¢Éúµþ¼ÓÊͷŵÄÏÖÏó£¬ÒÔ¼°²»Ò×ÊÜθҺpHÖµ±ä»¯µÄ¸öÌå²îÒìµÄÓ°Ïì¡£Òò´Ë£¬»ºÊÍ΢Í轺ÄұȻºÊÍƬ¸ü¾ßÓз¢Õ¹Ç°¾°¡£

¡¡¡¡ÎÒ¹úÔçÔÚ1977Äê°æµÄÖйúÒ©µä¾ÍÊÕÔØÁË·ÀÖÎѪÎü³æ²¡µÄûʳ×ÓËáÌàÄÆ»ºÊÍƬ£¬µ«ÔÚÕâ·½ÃæµÄÑо¿Ö±µ½80Äê´ú²Å±»¹ã·ºÖØÊÓ¡£1995ÄêÎÒ¹úÅú×¼µÄ»º/¿ØÊÍÖƼÁ¾ÍÓÐ7¸ö£¬Ö¬ÖÊÌ塢΢Çò¡¢ºÁ΢Á£µÈÑÇ΢Á£·ÖÉ¢¸øҩϵͳÒÔ¼°½á³¦¶¨Î»¸øҩϵͳÕâÀà¿Ú·þ°ÐÏò¸øÒ©ÖƼÁ¹úÄÚÑо¿Ò²ºÜ»îÔ¾(Ä¿Ç°Ö¬ÖÊÌåÒÑÓÐÅú×¼Éú²úµÄÆ·ÖÖ)¡£½ñ¾ÍÒÔϼ¸¸ö²àÃæ½øÐиÅÊö¡£

1¡¡ÐÂÐÍ»º/¿ØÊÍÖƼÁÑо¿¸Å¿ö

1.1¡¡Î¸ÄÚÖÍÁôÐÍ¿ØÊ͸øҩϵͳ£Û2£¬3£Ý¡¡¿É²ÎÔÄÓйØÎÄÏס£

1.2¡¡Âö³åʽ¸øҩϵͳ¡¡¸ù¾Ýʱ³½Ò©ÀíѧÑо¿£¬Ò©ÎïµÄÖÎÁÆ×÷Óᢲ»Á¼·´Ó¦ºÍÌåÄÚ¹ý³Ì¾ùÓÐʱ¼ä½ÚÂÉ£¬ÕâÒѳÉΪÉè¼Æ¶¨Ê±ÊÍÒ©ÕâÀà¿ØÊÍÖƼÁµÄÖØÒªÒÀ¾Ý¡£ÊÍÒ©·½Ê½·ûºÏÈËÌåÖçÒ¹½ÚÂɱ仯µÄ¹æÂÉ£¬ÕâÊǽü´úÒ©¼ÁѧÑо¿µÄÒ»ÖÖÐÂÐÍÊÍҩģʽ¡£¹úÍâÓжà¼ÒÖÆÒ©ÆóÒµÕýÔÚÑо¿¿ª·¢ÕâÀàÂö³åʽ¸øҩϵͳ£¬¹úÄÚÒàÒÑ¿ªÊ¼Ñо¿¡£

¡¡¡¡Âö³åÊÍҩϵͳ(pulsatile release system)¿Ú·þʱ½«ÒÔʱ¿ØµÄ·½Ê½ÔÚ賦µÀÄÚÌض¨²¿Î»ÊÍ·ÅÒ©Îï¡£ÕâÀà¸øҩϵͳÌرðÊÊÓÃÓÚÒ¹¼ä»òÐѺóÂíÉÏÐèÒªÓÐÒ»¸öѪŨ·åÖµµÄ¼²²¡(ÈçʧÃß¡¢Ïø´­¡¢¹Ø½ÚÑס¢¾Ö²¿È±ÑªÐÔÐÄÔಡµÈ)£¬Ò²ÊÊÓÃÓÚÔÚ³¦µÀ½Ïϲ¿Î»´¦ÊÍÒ©ºÍÎüÊÕµÄÄÇЩ¼²²¡(Èç½á³¦°©¡¢À£ÑñÐԽ᳦Ñס¢¿Ú·þëÄÀàµÈ)¡£Ä¿Ç°¹úÍâͶÈëÕâÀàÑо¿µÄÖ÷ÒªÓÐƽ´­Ò©¡¢ÐÄѪ¹ÜÒ©ºÍH2ÊÜÌå×è¶Ï¼Á¼°ÒȵºËصȡ£ÒýÈëעĿµÄÊÇALZA¹«Ë¾ºÍSearle¹«Ë¾¹²Í¬¿ª·¢µÄάÀ­ÅÁÃ×ÖçÒ¹½ÚÂÉÂö³åÊÍҩϵͳÉÌÆ·ÃûΪCalan- OROS¡£ÖÎÁÆʵ¼ùÖ¤Ã÷£º¸ßѪѹ»¼Õß×î¼Ñ¸øҩʱ¼äΪÇ峿3µã×óÓÒ£¬´Ëʱ»¼ÕßÌåÄÚ¶ù²è·Ó°·Ë®Æ½Ôö¸ß£¬ÐÄÔࡢѪ¹ÜÊÕËõ¼ÓÇ¿£¬Òò¶ø×î¿ÉÄܳöÎÊÌ⣬¸Ã¸øҩϵͳÍíÉÏÁÙ˯ǰ·þÓ㬴ÎÈÕÇ峿¿ÉÊÍ·ÅÂö³å¼ÁÁ¿µÄÒ©Îʮ·Ö·ûºÏ¸Ã²¡½ÚÂɱ仯µÄÐèÒª£¬Ô¤¼Æ¸Ã¼ÁÐͺܿ켴¿ÉÉÏÊС£

1.2.1¡¡Âö³åÊÍҩƬ¡¡°´Ê±¿Ø±À½â»úÖÆ(time-controlled disintegration mechanism)Éè¼ÆµÄÒ»ÖÖ¸Éѹ°üÒÂƬ¿É´ïÂö³åÊÍҩ֮ĿµÄ¡£ÆäƬоÓÉÒ©ÎïÓë±À½â¼Á×é³É£¬ÆäÍâ¿ÇÊÇÓÉË®Éø͸ÐÔСµÄ¸´ºÏ²ÄÁÏ×é³É¡£µ÷½ÚÍâ¿Çºñ¶ÈÓëË®Éø͸ÐÔ¼´¿É¿ØÖÆÆäÂö³åÊÍҩʱ¼ä¡£ÀýÈ磺ÒÔÑÎËáÁòµª?NFDA1?ͪΪģÐÍÒ©Îï(ÔڽϿíµÄ賦µÀÄڿɱ»ÎüÊÕ)£¬Ñ¡ÓÃôȼ׻ùÏËάËظÆ(ECG-505)×÷±À½â¼Á£¬Ó²Ö¬ËáþΪÈ󻬼ÁѹÖƳÉƬо¡£Íâ¿ÇÓÉÇ⻯±ÍÂéÓÍ(HCO)¡¢¾ÛÂÈÒÒÏ©(PVC)ºÍ¾ÛÒÒ¶þ´¼(PEG6000)»ìºÏ×é³É£¬²ÉÓÃ90¡«94¡æÈÛÈÚ·¨ÖÆÁ££¬È¡20Ä¿¿ÅÁ££¬ÒÔ¸Éѹ°üÒ·¨ÖÆƬ£¬µ÷½ÚPEGÓÃÁ¿¼°Íâ¿Çºñ¶È¼´¿É¿ØÖÆË®µÄÉø͸ËÙÂÊ¡£ÕâÖÖϵͳµÄƽ¾ùʱÖÍΪ(7±1)h£¬´ËʱҩÎïÔÚ15 minÄÚÊÍ·ÅÍê±Ï¡£

1.2.2¡¡Âö³åÊÍҩ΢Íè£Û4£Ý¡¡Òà³Æʱ¿Ø±¬ÁÑϵͳ(time-controlled explosion system£¬TES)¡£ÕâÖÖÇòÐÎ΢ÍèµÄ½á¹¹¿É·Ö4²ã£¬´ÓÀïµ½Íâ·ÖÍèо¡¢Ò©Îï²ã¡¢ÅòÕͼÁ²ã¼°Ë®²»ÈÜÐÔ¾ÛºÏÎïÍâ²ãÒÂĤ£¬¼ûͼ1¡£µ±Ë®·Ýͨ¹ýÍâ²ãÒÂĤÏòϵͳÄÚÉø͸£¬½Ó´¥ÅòÕͼÁ£¬Ò»µ©Ë®»¯ÅòÕͼÁµÄÅòÕÍÁ¦³¬¹ýÍâ²ãÒÂĤµÄ¿¹ÕÅÇ¿¶Èʱ£¬Ä¤¿ªÊ¼ÆÆÁÑ£¬´¥·¢Ò©ÎïÊÍ·Å¡£¿Éͨ¹ý¸Ä±äÍâ²ãÒÂĤµÄºñ¶ÈÀ´¿ØÖÆÊÍ·ÅÒ©ÎïµÄʱ¼ä¡£ÀýÈ磬ÍèоÓÃÌÇÍè(nonpareil)£¬ÆäÍâ²ãÒÀ´Î°üÉÏÒ©Îï²ã¡¢ÅòÕͲã(L-HPC)¼°Íâ²ãECĤ£¬µ±ÅòÕͲãºñ¶È(180 μm)¹Ì¶¨Ê±£¬ECĤ²ãµÄºñ¶È¿ÉÓ°ÏìÊÍÒ©µÄʱÖÍ(tL)£¬Èçθ¸´°²TES£¬ECĤºñΪ20 μmʱ£¬tLΪ1 h£»ECĤºñΪ25 μmʱ£¬tLΪ2 h£»ECĤºñΪ30 μmʱ£¬tLΪ3h¡£ÈôECĤ(25 μm)ºñ¹Ì¶¨£¬Ôòµ÷½ÚL-HPC²ãµÄºñ¶ÈÒà¿Éµ÷½ÚÊÍҩʱ¼ä£¬Èçtiap ride hydrochloride TES,ÔÚL-HPCΪ120 μmºñʱ£¬¾­Àú1hµÄʱÖͺóÊÍÒ©£¬µ«ÒÂĤ6hҲδÆÆ£»ÈôL-HPCΪ180 μmʱ£¬2hºóÒÂĤ¿ªÊ¼ÆÆÁÑ£¬6hÄÚÈ«ÆÆ£¬Ò©ÎïÊÍ·Åͬ²½½øÐС£¡¡¡¡TES¿ÉÊÊÓÃÓÚ¸÷ÖÖÀí»¯ÐÔÖʲ»Í¬µÄÒ©Îï¡£ÕâÀà¸øҩϵͳ¹úÄÚÒàÒÑ¿ªÊ¼Ñо¿¡£

1.3¡¡½á³¦¶¨Î»¸øҩϵͳ£Û5¡«11£Ý¡¡½á³¦²¿Î»¼²²¡ÈçÀ£ÑñÐԽ᳦Ñס¢½á³¦°©µÈÒªÇóÄÜÔڽ᳦²¿Î»ÊÍÒ©£»´ËÍ⣬Ëæ×ÅÉúÎ﹤³ÌµÄ·¢Õ¹£¬¶àëÄÀà¡¢µ°°×ÀàÒ©ÎïÔö¶à£¬ÕâÀàÒ©Îïͨ³£Òª×¢Éä¸øÒ©£¬ÒòËüÃÇÔÚ賦µÀÉ϶ÎÎȶ¨ÐÔ¼°ÎüÊÕÀûÓò¹Ê²»ÒË¿Ú·þ£¬¿ÉÊÇÔڽ᳦¶Î½µ½âµ°°×µÄøÀà½ÏÉÙ£¬ÍùÍùÎüÊÕÀûÓýϺã¬ÈôÄÜÖƳɽ᳦¶¨Î»¸øҩϵͳ£¬Ôò¶àëÄÀà¡¢µ°°×ÀàÒ©Îï¿Ú·þ¸øÒ©¾ÍÓÐÏ£Íû£¬Òò¶ø¹úÄÚÍâ¾ùÖÂÁ¦ÓÚÑÐÖÆ¿ª·¢ÕâÀàÐÂÐ͸øҩϵͳ¡£ÕâÀà¸øҩϵͳͨ³£¿ÉÓÉÏÂÁм¸ÖÖ²ÄÁÏÖƳɡ£

1.3.1¡¡pHÃô¸ÐµÄ³¦ÈܲÄÁÏ¡¡²ÉÓÃË«²ãÒÂĤ¿ØÖÆÒ©ÎïÔڽ᳦²¿Î»ÊÍ·Å¡£È磺½«ÏûÑ×Í´(25%W/W)¡¢ÈéÌÇ(62%W/W)¡¢µí·Û(10%W /W)»ìÔÈ£¬ÒÔ10%(W/V)PVPË®ÈÜҺʪÈóÖÆÁ££¬55¡æ¸ÉÔÕûÁ£ºó¼Ó1%M.S£¬ÒÔΦ 4.5 mm°¼³åѹƬºó°üHPMC»ºÊÍÒ²ã(ÔöÖØ35.7%£¬Å䷽Ϊ£ºMethocel K15 5.0,PEG400 1.0,Talc 2.0,PVP 2.5£¬ÒÒ´¼84.0£¬Ë®5.5)£¬ÔÙ°ü³¦Ò²ã(ÔöÖØ5%£¬Å䷽Ϊ£º8%(W/V)Eudragitl,2%DEP)¡£ÕâÀà²ÄÁÏÒ×Êܳ¦µÀpHÖµ±ä»¯µÄÓ°Ïì¡£

1.3.2¡¡Ê±¿ØÐͲÄÁÏ¡¡Í¨³£Ê³ÎïÔÚθ¼°Ð¡³¦·Ö±ðÖÍÁôÔ¼3h×óÓÒ£¬ËùÒÔʳÎïÔËÐÐÖÁ½á³¦Ô¼Ðè5¡«7h¡£ÈôÄÜ¿ØÖÆÔÚ5¡«7hÊÍÒ©Õß¼´¿É´ï½á³¦¸øҩ֮Ч¡£Ç°Êöʱ¿ØÐÍÂö³åÊÍҩϵͳ¼´Êô´ËÀ࣬ÕâÀà¸øҩϵͳÒò¸÷ÈËθÅÅ¿ÕËÙÂʲ»Í¬£¬ËùÒÔ¸öÌå²îÒì½Ï´ó¡£

1.3.3¡¡Ã¸Ïû»¯ÐͲÄÁÏ¡¡ÀûÓý᳦²¿Î»ÌØÓеÄ΢ÉúÎïËù²úÉúµÄø£¬ÒÔ½µ½â¸ß·Ö×Ó²ÄÁ϶øÊÍÒ©£¬ÀýÈ磬żµª¾ÛºÏÎï¡¢¹û½ºµÈ¿É±»½á³¦ÖÐÌØÓеÄ΢ÉúÎïø½µ½â¶øÊÍÒ©¡£ÕâÀà²ÄÁϽ᳦¶¨Î»µÄרÊôÐÔ½ÏÇ°Á½ÀàÇ¿¡£

1.3.4¡¡ÆäËû¡¡²ÉÓøßƵ½ºÄÒ£¬ÔÚ½º¿ÇÉÏ×°Ò»¸ö΢ÐÍÏßȦ£¬ÔÚ¸ßƵ´Å³¡×÷ÓÃÏÂÏßȦ²úÉúµçÁ÷£¬Òý·¢½º¿ÇÆÆÁѶøÊÍÒ©¡£

1.4¡¡×Ô¶¯µ÷½Ú¸øҩϵͳ£Û12£¬13£Ý¡¡¿É²ÎÔÄÓйØÎÄÏס£

2¡¡°ÐÏò¸øҩϵͳÑо¿ÏÖ×´

¡¡¡¡ÔÚÁÙ´²ÖÎÁƼ²²¡µÄ¹ý³ÌÖÐÍùÍùÐèÒªÌá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£¬ÒÔÆÚ×î´óÏ޶ȵØÔöÇ¿Ò©ÎïµÄÁÆЧ£¬Í¬Ê±Ê¹Ò©ÎïµÄ²»Á¼·´Ó¦½µÖÁ×îµÍ£¬Òò´Ë°ÐÏò¸øҩϵͳ(TDDS)ÒѳÉΪÏÖ´úÒ©¼ÁѧµÄÖØÒªÄÚÈÝ¡£Í¨³£¿É½«¿ØÊÍÖƼÁ·Ö³ÉÁ½´óÀࣺһÀàרÃÅÑо¿ÈçºÎ¿ØÖÆÖƼÁÖÐÒ©ÎïÊͷŵÄËٶȣ¬¼´Á㼶¡¢Ò»¼¶»¹ÊÇÂö³åʽÊÍÒ©£¬ÒÖ»ò×Ôµ÷ʽÊÍÒ©µÈµÈ(ÒÑÔÚÇ°ÊöÄÚÈÝÖÐÌÖÂÛ)£»ÁíÒ»ÀàרÃÅÑо¿ÈçºÎ¿ØÖÆÖƼÁÖÐÒ©ÎïÊͷŵÄÈ¥Ïò£¬ÕâÊÇÒ»ÀàÒªÇó¸ü¸ß¡¢ÄѶȸü´óµÄÐÂÖƼÁ£¬Òò¶ø½«Æä¹éÊôÓÚ°ÐÏòÖƼÁ½øÐе¥ÁÐÌÖÂÛ¡£

2.1¡¡°ÐÏò¸øÒ©ÖƼÁµÄ·ÖÀà

2.1.1¡¡°´¸øҩ;¾¶·Ö¡¡È«Éí×÷ÓðÐÏò¸øÒ©ÖƼÁ£¬¼´Í¨¹ý¿Ú·þ»ò×¢ÉäµÈ·½Ê½¸øÒ©ºó£¬ÄÜʹҩÎïµ¼ÏòËùÐè·¢»Ó×÷ÓõIJ¿Î»£»·ÇÈ«Éí×÷ÓõİÐÏò¸øÒ©ÖƼÁ£¬¼´¾Ö²¿ÓÃÒ©ºó£¬Ò©Îï¾ÍÔڸò¿Î»·¢»ÓÖÎÁÆ×÷Óá£

2.1.2¡¡°´×÷Ó÷½Ê½·Ö¡¡Ö÷¶¯°ÐÏò(active targeting)¸øÒ©ÖƼÁ¾ßÓÐʶ±ð°Ð×éÖ¯»ò°Ðϸ°ûµÄ´ó·Ö×Ó£¬ÒÔÆäΪÔØÌåµÄÄÜÁ¦£»±»¶¯°ÐÏò(passive targeting)¸øÒ©ÖƼÁ£¬ÏñÖ¬ÖÊÌ塢΢Çò¡¢ºÁ΢Á£¡¢Èé¼Á»ò¸´ÈéµÈ΢Á£ÔØÌåÖƼÁ£¬¶Ô°Ðϸ°û²¢ÎÞʶ±ðÄÜÁ¦£¬µ«¿É¾­ÑªÑ­»·µ½´ïËüÃDz»ÄÜͨ¹ýµÄëϸѪ¹Ü´²£¬²¢Ôڸò¿Î»ÊÍÒ©¡£

2.1.3¡¡°´Ò©Îï×÷ÓÃˮƽ·Ö¡¡Ò»¼¶°ÐÏò£¬Èç΢Á£ÔØÌåÖƼÁÖ»Äܽ«Ò©ÎïÊäËÍÖÁÌض¨µÄÆ÷¹Ù£»¶þ¼¶°ÐÏò£¬ÏµÖ¸Äܽ«Ò©ÎïÊäËÍÖÁijÆ÷¹ÙµÄÌض¨²¿Î»£»Èý¼¶°ÐÏò£¬ÏµÖ¸Äܽ«Ò©ÎïÊäËÍÖÁÌض¨²¿Î»µÄ²¡±äϸ°ûÄÚ¡£ÈçÈôÄܽ«Ò©ÎïÖƳÉÈý¼¶°ÐÏòÖƼÁ£¬Ôò¿ÉʹҩÎïÔÚϸ°ûˮƽÉÏ·¢»Ó×÷Óã¬Ò©Îï¿ÉרÃŹ¥»÷²¡±äϸ°û£¬¶ÔÕý³£Ï¸°ûûÓлò¼¸ºõûÓв»Á¼µÄÓ°Ï죬¿ÉʹҩÎïµÄÁÆЧ´ïµ½×îÀíÏëµÄ³Ì¶È¡£

2.1.4¡¡°´ÎïÀíÐÎ̬·Ö¡¡Ë®²»ÈÜÐÔÖƼÁÖ¸Ö¬ÖÊÌ塢΢Çò¡¢ºÁ΢Á£¡¢Èé¼Á»ò¸´ÈéµÈË®²»ÈÜÐÔ΢Á£ÔØÌåÖƼÁ£»ÁíÒ»ÀàÊÇË®ÈÜÐÔµÄÌØÒì»ò·ÇÌØÒìÐÔ´ó·Ö×ÓÔØÌåÖƼÁ£¬°üÀ¨ºÏ³É´ó·Ö×ÓÓëÌìÈ»µÄÉúÎï´ó·Ö×Ó(Èç¾Û¶àÌÇ¡¢¿¹Ìå¡¢ºËÌÇ¡¢ºËËáµÈ)ÔØÌåÖƼÁ£¬Ò©ÎïµÄ°ÐÏòÖ÷Ҫƾ½èÔØÌåϵͳÀ´ÊµÏÖ£¬¹ÊÓֿɳÆΪҩÎïÔØÌåϵͳ (drug-carrier systems)¡£

ÎÄÏ××ÊÁϾ­³£²ÉÓÃÖ÷¶¯°ÐÏòÓë±»¶¯°ÐÏò¸øÒ©ÖƼÁµÄ·ÖÀà·¨¡£

¡¡¡¡ÔÚÒÔÍùÑо¿ÖУ¬±»¶¯°ÐÏò¸øÒ©Ñо¿½Ï¶à£¬ÈçÖ¬ÖÊÌåµÈ΢Á£ÔØÌåÖƼÁ£¬½øÈë»úÌåºó£¬¿É°´ÆäÁ£¾¶´óС·Ö²¼ÓÚ²»Í¬µÄÔàÆ÷£º¾²Âö×¢Éä7¡«12 μmµÄ΢Á££¬¿É±»·Î²¿»úеÐÔ½ØÂ˶øÉãÈ¡£»¶¯Âö×¢Éä´óÓÚ12 μmµÄ΢Á££¬¿É×èÖÍÓÚëϸѪ¹Ü´²¶øµ½´ï¸Î¡¢ÉöºÉÁöÆ÷¹ÙÖУ»¾²Âö¡¢¶¯Âö»ò¸¹Ç»×¢Éä0.1¡«0.2 μmµÄ΢Á££¬ºÜ¿ì±»Íø×´ÄÚƤϵͳ(RES)µÄ¾ÞÊÉϸ°ûÍÌÊÉ×îÖÕµ½´ï¸ÎÔà¿Ý·ñÊÏϸ°ûµÄÈÜøÌåÖС£

2.2¡¡°ÐÏò¸øҩϵͳ·¢Õ¹Ç÷ÊÆ¡¡Îª½øÒ»²½Ìá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£Û14£¬15£Ý£¬¿Æѧ¼ÒÃÇÓÖ½«ÄÜʶ±ð°Ðϸ°ûµÄ´ó·Ö×ÓÁ¬½ÓÓÚÒ©ÎïÔØÌåµÄ±íÃæ(»òÓëÒ©Îï·Ö×ÓÖ±½ÓÏàÁª)£¬È磺½«µ¥¿Ë¡¿¹ÌåÁ¬½ÓÓÚº¬Ò©Ö¬ÖÊÌå(»òºÁ΢Á£)µÄ±íÃ棬¿ÉÌá¸ßÒ©Îï¶ÔÖ×Áöϸ°ûµÄ°ÐÏòÐÔ£¬µ«ÒòʵÌåÁöÄÚѪ¹©²î£¬ËüÏòÁöÌåÄÚ²¿°ÐÏòµÄЧ¹ûÒà²î£»½ø¶øÑÐÖÆÈËÊóǶºÏ¿¹Ö×Áöϸ°ûºËµ¥¿Ë¡¿¹Ìå(chTNT)Ö¬ÖÊÌ壬ʹÆä°ÐÏòʵÌåÁöÄÚµÄЧ¹û±Èµ¥¿¹Ö¬ÖÊÌå´óΪÌá¸ß£¬ÕâÖÖÃâÒßÐÍÖ¬ÖÊÌå×÷ΪҩÎï´«ÊäϵͳµÄÑо¿±¨µÀËäΪÊý²»¶à£¬µ«Ä¿Ç°ÒÑÊܹúÄÚÍâѧÕßµÄÆÕ±é¹Ø×¢¡£

¡¡¡¡Ñо¿±íÃ÷¶àÊýÖ×Áöϸ°û±íÃæÉϵÄÒ¶ËáÊÜÌ壬ÔÚÊýÁ¿ºÍ»îÐÔÉϾù±ÈÕý³£Ï¸°û´óµÃ¶à£¬Òò¶ø¿ÉÖƱ¸Ò¶ËáÖ¬ÖÊÌ壬ËüÒÔÒ¶ËáÊÜÌåΪ½éµ¼£¬Ìá¸ßÁËÖ¬ÖÊÌå¶ÔÖ×Áöϸ°ûµÄ°ÐÏòÐÔ¡£

¡¡¡¡Ò¶ËáÖ¬ÖÊÌåÒ×µ¼Ïò“½¡¿µ”Ö×Áöϸ°ûĤ£¬¹ÊΪ·ÇÍíÆÚÖ×ÁöÖÎÁÆÒ©ÎïµÄÓÅÁ¼´«Êäϵͳ£»chTNT-Ö¬ÖÊÌåÒ×´©Í¸“²»½¡¿µ”Ö×Áöϸ°ûĤ¶ø°ÐÏòϸ°ûºË£¬¹ÊΪÍíÆÚÖ×ÁöÖÎÁÆÒ©ÎïµÄÓÅÁ¼´«Êäϵͳ£¬ÕâÑùÁ½ÖÖ²»Í¬µÄ°ÐÏòÖ¬ÖÊÌå¿ÉÓÃÓÚÖÎÁƲ»Í¬Éú³¤ÆڵĹãÆ×Ö×Áö¡£

¡¡¡¡1966ÄêMorellµÈ·¢ÏÖ²¸È鶯ÎïµÄ¸ÎʵÖÊϸ°ûĤ±íÃæ´æÔÚÈ¥ÍÙÒºËáÌǵ°°×ÊÜÌå(Asialoglycoprotein receptor,ASGPr)£¬¸ÃÊÜÌåÄÜרһÐÔµØʶ±ðÒÔ°ëÈéÌÇΪ¶Ë»ùµÄÌǵ°°×£¬Òò¶øÒÔÕâÑùµÄÌǵ°°×ΪÔØÌ壬¿É½«Ò©Îïµ¼Ïò¸ÎʵÖÊϸ°û(¸Î·ÇʵÖÊϸ°û(¿Ý·ñÊÏϸ°ûºÍÄÚƤϸ°û)µÄ±íÃæÓиʶÌÇÊÜÌå)£¬²¢Ö÷¶¯Ïò¸Îϸ°ûµÄÈÜøÌåתÔË£¬¶øÊÜÌå±¾ÉíÓÖÄÜÖØлص½Ï¸°ûĤ¡£

¡¡¡¡Ä¿Ç°¹úÄÚÍâ¶ÔÊÜÌåÐÍÓëÃâÒßÐÍ°ÐÏòÖƼÁÑо¿±¨µÀ½Ï¶à£¬Í¨¹ýÕâÁ½Öֽ鵼·½Ê½ÒÔÌá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£¬Ê¹Ò©Ð§·¢»ÓµÃ×îºÃ£¬²»Á¼·´Ó¦½µÖÁ×îС¡£

¡¡¡¡»¹¿É½«Ò©ÎïÖƳɴÅÐÔÖƼÁ£¬ÒÔÌá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£¬È纬³¬Î¢´ÅÁ£µÄÑÎËᰢùËص°°×΢Çò£¬¶¯Âö×¢Éäºó£¬ÔÚ°ÐÇøÌåÍâ´Å³¡µÄÒýµ¼Ï£¬Æä°ÐÇøÒ©ÎïŨ¶È±È¾²Âö×¢Éäͬ¼ÁÁ¿µÄÓÎÀ밢ùËظ߳ö100±¶¡£ÁÙ´²ÊÔÑé±íÃ÷£¬´ÅÐÔÖƼÁÖеĴÅÐÔ³¬Î¢Á£×Ó¿ÉÒÔ¶¨ÆÚ°²È«µØ±»ÅųöÌåÍâ¡£µ«ÉдæÔڴų¡µÄÇ¿¶È¡¢ÌݶÈÓ듾۽¹”ÎÊÌ⣬´Å³¡ÊÇ·ñ»á¸Ä±äºìϸ°ûµÄ»úÄܺ͸ıäѪÁ÷µÄ·½Ê½µÈÎÊÌ⣬¾ùÓдý½øÒ»²½Ñо¿¡£

¡¡¡¡µÍÃܶÈÖ¬µ°°×(LDL)£Û16£ÝÊÇ´æÔÚÓÚ²¸È鶯ÎïѪ½¬ÖеÄÖ¬µ°°×¡£ÈËѪ½¬ÖÐLDL¿ÉЯ´øѪ½¬µ¨¹Ì´¼×ÜÁ¿µÄ2/3£¬ÊÇϸ°ûÍâÔ´ÐÔµ¨¹Ì´¼µÄÖ÷ÒªÀ´Ô´¡£LDLÌåÄÚ´úлÖ÷Òª¾­ÓÉϸ°ûĤ±íÃæµÄÌØÒìÐÔLDLÊÜÌåʶ±ð£¬´Ó¶ø½øÈëϸ°ûÄÚ±»ÀûÓã¬ÔÚϸ°ûÄÚµÄÄÚÔ´ÐÔµ¨¹Ì´¼²»ÄÜÂú×ãÐèҪʱ£¬Í¨¹ýµ÷½Úϸ°ûĤÉÏLDLÊÜÌåµÄÊýÄ¿ºÍ»îÐÔ£¬ÒÔÔö¼Ó¶ÔLDLµÄÎüÊÕ¶øÔö¼Ó¶ÔÍâÔ´ÐÔµ¨¹Ì´¼µÄÀûÓá£LDLÖ÷Òª¾­¸ÎÄÚÌض¨µÄLDLÊÜÌåÇå³ý¡£°©Ï¸°û³£¾ßÓÐÄÚÔ´ÐÔµ¨¹Ì´¼ºÏ³ÉÕÏ°­£¬ÇÒÓÉÓÚÆä´óÁ¿ÔöÖ³¸´ÖÆ£¬Ï¸°ûĤ¶Ôµ¨¹Ì´¼µÄ´óÁ¿ÐèÇó£¬Ï¸°û±íÃæLDLÊÜÌåµÄ»îÐÔ¼°ÊýÁ¿ÔÚijЩ°©Ï¸°ûÖи߳öÕý³£Ï¸°û20±¶ÒÔÉÏ£¬Òò´Ë£¬²ÉÓÃLDLºÉÔØ¿¹°©Ò©Î¿É´ó´óÌá¸ß¶ÔijЩ°©Ï¸°ûµÄ°ÐÏòÐÔ¡£LDLÊÇÄÚÔ´ÐÔÖ¬µ°°×£¬½«Ëü×÷ΪҩÎïÔØÌ壬¼´¿É±ÜÃâÖ¬ÖÊÌå¡¢µ¥¿Ë¡¿¹ÌåµÈÔÚÌåÑ­»·Öб»Íø×´ÄÚƤϵͳѸËÙÇå³ýµÄÎÊÌ⣬ÓÖ¿ÉÃÖ²¹Ò»°ãÔØÌå´æÔڵİÐÏòÐÔ²îµÄ²»×㣬Õâ¶Ô½â¾öµ±Ç°¿¹°©Ò©ÎﻯÁÆÖдæÔڵİÐÏòÐԲ²»Á¼·´Ó¦´óµÄÎÊÌâ¾ßÓÐÖØÒªÒâÒå¡£

¡¡¡¡ÔÚϸСµÄÒ©ÎïÔØÌå΢Á£½øÈëÌåÑ­»·Ê±Ò×±»RESµÄ¾ÞÊÉϸ°ûÍÌÊÉ£¬´Ó¶øÓ°ÏìÒ©Îïµ½´ïËùÐèÖÎÁƵİÐÇø£¬¹Ê´Ë£¬»Ø±ÜRESµÄÍÌÊÉ×÷ÓÃÒѳÉΪҩÎïÔØÌå°ÐÏòÐÔµÄÖصã¿ÎÌâÖ®Ò»£Û17£¬18£Ý¡£Èô½«¿Õ°×ÔØÌåÏÈÓÃRES±¥ºÍ£¬È»ºóÔÙ¸øº¬Ò©ÔØÌ壬¼´¿ÉÖ±´ï°ÐÇø£¬µ«´Ë¾Ù»áʹ»úÌåÃâÒß¹¦ÄÜÊÜË𣬲¢°é·¢ÆäËû¼²²¡£¬¹Ê´Ë·¨²»¿ÉÈ¡£»ÈôÒÔ»úÌåÄÚÔ´ÐÔÎïÖÊÈçLDLΪÔØÌ壬Ôò¿É»Ø±ÜRESµÄÍÌÊÉ¡£½üÄêÀ´Ñо¿½Ï¶àµÄÊǻرÜRESµÄÃâÒßÖ¬ÖÊÌå(RES-avoiding immunoliposomes)£¬¼´ÔÚº¬Ò©Ö¬ÖÊÌåµÄ±íÃæ¼ÈÓÐIgGÃâÒß¿¹Ì壬ÓÖ¹üÒÔPEG£¬¼ûͼ2¡£ÕâÑù¼È»Ø±ÜÁ˾ÞÊÉϸ°ûµÄÍÌÊÉ£¬Óֿɽ«Ò©Îïµ¼Ïò°Ðϸ°û¡£PEG¿É»Ø±ÜRESÍÌÊɵĻúÖÆËäδÍêÈ«¸ãÇ壬µ«ÕâÓëPEG·Ö×Ӿ߶ÀÌؽṹÓйأ¬¼´ÓëÆäÇ¿Ç×Ë®ÐÔºÍÓÐÒ»¶¨µÄ÷·¸ï¡¡ÈÐÐÔÓйأ¬ÍƲâPGE¾ßÓÐÄ£·Â°×ϸ°û¡¢ºìϸ°û±íÃæ´æÔڵĶàÌÇ»ùÒòµÄ¹¦ÄÜ¡£ÓÖÈç»Ø±ÜRESµÄ·ÇÀë×Ó±íÃæ»îÐÔ¼ÁÄÒÅÝ(nonionic surfactant vesicles,NsVs¼´Niosomes)£¬ÓÉPEG2000-µ¨¹Ì´¼ÑÜÉúÎï(PEG-ch)ÖƳɵij¤Ñ­»·°¢Ã¹ËØ·ÇÀë×Ó±íÃæ»îÐÔ¼ÁÄÒÅÝ(long circulation adriamycin NsVs,L-ADM-NsVs)£¬Æä±íÃæÉϵÄPEG²ãÔöÇ¿Á˸ÃÄÒÅݵÄÇ×Ë®ÐÔ£¬´Ó¶ø¼õÉÙRESµÄÍÌÊÉ£¬ÑÓ³¤ÑªÖÐÑ­»·Ê±¼ä£¬Ìá¸ß°ÐÏòÐÔºÍÒÖÁö»îÐÔ¡£

²Î¿¼ÎÄÏ×

¡¡1¡¡Ansel HC,Popovich NG,Allen LV.Pharmaceutical dosage forms and drug delivery systems.Williams & Wilkins Baltimore.6th ed.New York:Marcel Dekker Inc,1995.218¡«220

¡¡2¡¡Deshpande AA,Shah NH,Rhodes CT,et al.Development of a novel controlled-release system for gastric retention.Pharm Res,1997,14(6)¡Ã815

¡¡3¡¡Shalaby WSW,Blevins WE,Park K.In vitro and in vivo studies of enzyme-digesbible hydrogels for oral drug delivery.J Controlled Release,1992,19(1¡«3)¡Ã131

¡¡4¡¡Ueda S,Yamagulchi H,Kotani M,et al.Development of a novel drug release system,time-controlled explosion system(TES)¢ò.Chem Pharm Bull,1994,42(4)¡Ã246

¡¡5¡¡Bieck PR.Colonic drug absorption and metabolism.New York:Marcel Dekker Inc,1993.169¡«172

¡¡6¡¡Gazzanig A,Sangalli ME,Giordano F.Oral chronotopic drug delivery systems:achievement of time and/or sit specifity.Eur J Pharm Biopharm,1994,40(4)¡Ã246

¡¡7¡¡Rubinstein A,Radai R,Ezra M,et al.In vitro evaluation of calcium pectinate:a potential colon-specific drug delivery carrier.Pharm Res,1993,10(2)¡Ã258

¡¡8¡¡Ashford M,Fell J,Attwood D,et al.Studies on pectin formulations for colonic drug delivery.J Controlled Release,1994,30(3)¡Ã225

¡¡9¡¡Leopold CS,Friend DR.A dexamethasone-poly (L-aspartic acid) conjugate as potential prodrug for colon-specific drug delivery.Eur J Pharm Biopharm,1996,42(Suppl 1)¡ÃS485

10¡¡Bieck PR.Colonic drug absorption and metabolism.New York:Marcel Dekker Inc,1993.145¡«148

11¡¡Sako K,Nakashima H,Sawada T,et al.Relationship between gelation rate of controlled-release acetaminophen tablets containing ployethylene oxide and colonic drug release in dogs.Pharm Res,1996,13(4)¡Ã549

12¡¡Anderson JM,Kim SW,Kope¨¯ch J,et al.Advances in drug delivery systems 5.London£¬New York,Tokyo:Elsevier Amsterdam,1992.145¡«159

13¡¡Kitano S,Koyamay ,Kataoka K,et al.A novel drug delivery system utilizing a glucose responsive polymer complex between poly(vinyl alcohol)and poly(N-vinl-2-pyrrolidone)with a phenylboronic acid moiety.J Controlled Release,1992,19(1¡«3)¡Ã161

14¡¡Gottschalk S,Cristiano RJ,Smith LC,et al.Folate receptor mediated DNA delivery into tumor cells:potosomal disruption results in enhanced gene expression.Gene Ther,1994,1(1)¡Ã185

15¡¡Rojansakuly.Antisense oligonucleotide therapeutics:drug delivery and targeting.Adv Drug Delivery Rev,1996,18(2)¡Ã115

16¡¡Bijsterbosch MK,Berkel TJCV.Native and modified lipoproteins as drug delivery systems.Adv Drug Delivery Rev,1990,5(3)¡Ã231

17¡¡Herron JN,Gentry CA,Davies SS,et al.Antibodies as targeting moiesties:affinity measurements conjugation chemistry and applications in immanoliposomes.J Controlled Release,1994,28(1¡«3)¡Ã155

18¡¡Kuke I,Hayashi T,Tabata Y,et al.Synthesis of poly (ethylene glycol)derivatives with different branchings and their use for protein modification.J Controlled Release,1994,30(1)¡Ã27


ÁúÊ¢¹ú¼ÊappÏÂÔØ_±¸ÓÃÍøÕ¾ÓÎÏ·~

ÈÈ°ñÔĶÁTOP

±¾ÖÜTOP10

2050ÀýӲĤÍâ×èÖÍÒ©ÎïÀ©É¢ÔÙÈÏʶ

2050ÀýӲĤÍâ×èÖÍÒ©ÎïÀ©É¢ÔÙÈÏʶ

£ÛÕªÒª£Ý Ä¿µÄ ̽ÌÖӲĤÍâ×èÖͳõÁ¿ÔÚ²»Í¬´©´ÌµãµÄÀ©É¢Çé¿ö¡£×ÊÁÏÓë·½·¨ 2050ÀýӲĤÍâ×èÖͲ¡Àý£¬Ïêϸ¼Ç¼...